CytomX Therapeutics is a clinical-stage company developing Varseta-M, a masked antibody-drug conjugate aimed at EpCAM, for colorectal and other gastrointestinal cancers; it is not approved.
CytomX's case rests on varsetatug masetecan (Varseta-M), a masked EpCAM-directed antibody-drug conjugate designed to switch on mainly inside tumors, in advanced colorectal cancer. A dose-selection update from its 113-patient Phase 1 is due by the end of 2026, and CytomX plans its first registrational trial in the first half of 2027. Cash of $330.3 million, plus $37 million received from Regeneron in July, should last at least into the second half of 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The year-end update supports a registrational dose
Do the optimization cohorts support a dose with durable responses and manageable toxicity?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Varseta-M heads toward a registrational colorectal cancer trial in 1H 2027, with a dose-selection update by year-end
CX-2051 Phase 1 positive interim data in advanced CRC
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
17 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.